Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02789020 · ClinicalTrials.gov registry record · Phase 2
Image Parkinson's Disease Progression Study
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT02789020 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 96 participants.
The verdict
NCT02789020, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
Parkinson's disease (PD) is a neurodegenerative brain disorder that impairs the ability to perform functions such as grooming, dressing, cooking, and other activities of daily living. PD affected between 4.1 and 4.6 million people worldwide in 2005, and it is projected that up to 9.3 million people will be affected by 2030. Although current pharmacological therapies provide beneficial effects on motor symptoms of the disease (tremor, rigidity, and bradykinesia), intolerable disability eventually develops in most patients. A disease-modifying therapy that slows disease progression is a major unmet medical need in PD. Numerous agents have neuroprotective effects in pre-clinical laboratory models, but none have been shown to have indisputable disease-modifying effects in clinical trials for patients with PD. The purpose of this research study is to investigate how the brain and motor behavior changes in PD over time in response to rasagiline which is a monoamine oxidase-B(MAO-B) inhibitor. The drug rasagiline will be tested in this study as the MAO-B inhibitor. Rasagiline has been prescribed for many years to treat symptomatic Parkinson's disease. It is FDA approved for the treatment of Parkinson's disease but has not been shown to slow disease progression. The outcome and impact of this study will provide the first evaluation of MAO-B inhibitors at slowing the progression of the nigrostriatal pathway using advanced Magnetic Resonance Imaging (MRI) and functional Magnetic Resonance Imaging (fMRI) methods in PD.
Interventions
- OTHER Placebo
- DEVICE Magnetic Resonance Imaging
- DRUG Rasagiline
- DEVICE functional Magnetic Resonance Imaging
- OTHER Physical Function Performance Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-12 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02789020
The ClinicalTrials.gov registry entry for NCT02789020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02789020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02789020 about?
NCT02789020 is a clinical study titled "Image Parkinson's Disease Progression Study". Parkinson's disease (PD) is a neurodegenerative brain disorder that impairs the ability to perform functions such as grooming, dressing, cooking, and other activities of daily living. PD affected between 4.1 and 4.6 million people worldwide in 2005, and it is projected that up to 9.3 million people ...
What is the current status of trial NCT02789020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2016-12. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT02789020?
The interventions under investigation include: Placebo (OTHER), Magnetic Resonance Imaging (DEVICE), Rasagiline (DRUG), functional Magnetic Resonance Imaging (DEVICE), Physical Function Performance Test (OTHER).
Who is sponsoring clinical trial NCT02789020?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.